fda warning letter hims & hers compounded semaglutide september 2025 Health addresses scrutiny of GLP-1 compounding| STAT Hims & Hers (HIMS) Shares

A phase I study of BOS172738 in patients with advanced solid tumors with RET gene alterations including non-small cell lung cancer and medullary thyroid cancer [abstract]

Olausson EA, Storsrud S, Grundin H, Isaksson M, Attvall S, Simren M

Our core capabilities include Polymer Synthesis and Characterization , Peptide Characterization , Organic Synthesis , Nitrosamine Testing and Analysis , PFAS Testing , and Extractable & Leachable Studies , as well as a broad suite of analytical techniques such as HPLC , GC-MS , MALDI-TOF , NMR , and FTIR

Sinai Hospital, who provided an overview of the known and potential AEs of GLP-1-based therapies

Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as an Add-on to Metformin, Thiazolidinediones, or Both, in Patients With Type 2 Diabetes (SUSTAIN 2): A 56-Week, Double-Blind, Phase 3a, Randomised Trial

Nausea, vomiting, and nutritional deficiencies become much harder to manage